Quotient Sciences, a global drug development services provider, and Vasa Therapeutics, a biopharmaceutical company developing novel therapies for heart failure, have announced the dosing of the first subjects in their Phase I clinical trial of VS-041. The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of VS-041 in healthy volunteers.
VS-041 is a novel therapeutic candidate designed to target the underlying mechanisms of heart failure. The Phase I trial will assess the safety and tolerability of escalating doses of VS-041, as well as its pharmacokinetic profile. The trial will also provide important information on the potential therapeutic window for VS-041.
The dosing of the first subjects marks an important milestone in the development of VS-041 and represents a significant step forward in Vasa Therapeutics' mission to develop innovative treatments for heart failure.
“We are excited to initiate this Phase I clinical trial and look forward to gathering important data on the safety and pharmacokinetics of VS-041,” said Dr. John McDonald, Chief Medical Officer at Vasa Therapeutics. “This is a critical step in our efforts to bring new and effective treatments to patients with heart failure.”
Quotient Sciences is providing comprehensive clinical trial services for the study, including study design, execution, and data analysis. The company’s expertise in early-phase drug development will support the successful completion of the trial and contribute to the advancement of VS-041.
For more information about the trial and VS-041, please visit Quotient Sciences’ website or contact Vasa Therapeutics directly.
